Abstract: An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: M(L1)n1(L2)n2??Formula 1 wherein, in Formula 1, M, L1, L2, n1, and n2 are each described herein.

Abstract: The present invention relates to a series of novel phenylaminopyridine derivatives and a use thereof for inhibiting capsid assembly and for preventing or treating virus infectious diseases thereby.

Abstract: An organic light-emitting device comprising: a first electrode; a second electrode facing the first electrode; and an organic layer disposed between the first electrode and the second electrode, wherein the organic layer comprises an emission layer, the emission layer comprises a first host and a dopant, the dopant is an organometallic compound including platinum, the organic light-emitting device satisfies a condition of: HOMO(D)?HOMO(Host 1)?0.2 electron volts, HOMO(D) is a highest occupied molecular orbital (HOMO) energy level of the dopant in electron volts, HOMO(Host 1) is a HOMO) energy level of the first host in electron volts, and HOMO(D) and HOMO(Host 1) are each measured using a photoelectron spectrometer in an ambient atmosphere.

Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.

Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.

Abstract: An organic light-emitting device including a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second electrode, wherein the organic layer includes an emission layer, the emission layer includes a host, a dopant, and a sensitizer, the host does not include a metal atom, the dopant emits light, and the light has a decay time of about 100 nanoseconds or less, and the sensitizer includes an organometallic compound represented by one selected from Formulae 1 and 2 described in the specification.

Abstract: A composition including a platinum-containing organometallic compound, a first compound, a second compound, and a third compound, and an organic light-emitting device including the same wherein the composition does not comprise iridium, the Pt-containing organometallic compound, the first compound, the second compound, and the third compound are different from each other, the first compound comprises at least one electron transport moiety, the second compound and the third compound do not include a metal, each of an absolute value of a HOMO energy level of the second compound and an absolute value of a HOMO energy level of the third compound is 5.30 eV to 5.85 eV, the difference between the absolute value of the HOMO energy level of the second compound and the absolute value of the HOMO energy level of the third compound is 0.01 eV to 0.30 eV.

Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.

Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.

Abstract: An organometallic compound represented by Formula 1: M(L1)n1(L2)n2??Formula 1 wherein, in Formula 1, M, L1, L2, n1, and n2 may be understood by referring to the descriptions of M, L1, L2, n1, and n2 respectively as disclosed herein.

Abstract: An organometallic compound represented by Formula 1:2 wherein, in Formula 1, groups and variables are the same as described in the specification.

Abstract: An organic light-emitting device comprising: a first electrode; a second electrode facing the first electrode; and an organic layer disposed between the first electrode and the second electrode, wherein the organic layer comprises an emission layer, the emission layer comprises a first host and a dopant, the dopant is an organometallic compound including platinum, the organic light-emitting device satisfies a condition of: HOMO(D)?HOMO(Host 1)?0.2 electron volts, HOMO(D) is a highest occupied molecular orbital (HOMO) energy level of the dopant in electron volts, HOMO(Host 1) is a HOMO) energy level of the first host in electron volts, and HOMO(D) and HOMO(Host 1) are each measured using a photoelectron spectrometer in an ambient atmosphere.

Abstract: The present invention relates to an anti-hepatitis B virus (HBV) composition containing ciclopirox or a pharmaceutically acceptable salt thereof; a pharmaceutical composition for preventing or treating an HBV-induced disease, which contains ciclopirox or a pharmaceutically acceptable salt thereof; a method for treating an HBV-induced disease, which includes a step of administering the pharmaceutical composition to a subject; and a health functional food composition for preventing or improving an HBV-induced disease, which contains ciclopirox or a physiologically acceptable salt thereof. The present invention has newly elucidated the HBV-inhibiting effect of ciclopirox, and overcame the problem of the existing drugs that cccDNA cannot be removed by monotherapy. In addition, the present invention provides a therapeutic agent capable of effectively inhibiting HBV by inhibiting core assembly during the life cycle of the virus.

Abstract: Provided are an organometallic compound, an organic light-emitting device including the same, and a diagnostic composition including the same.

Abstract: A composition including a platinum-containing organometallic compound, a first compound, a second compound, and a third compound, and an organic light-emitting device including the same wherein the composition does not comprise iridium, the Pt-containing organometallic compound, the first compound, the second compound, and the third compound are different from each other, the first compound comprises at least one electron transport moiety, the second compound and the third compound do not include a metal, each of an absolute value of a HOMO energy level of the second compound and an absolute value of a HOMO energy level of the third compound is 5.30 eV to 5.85 eV, the difference between the absolute value of the HOMO energy level of the second compound and the absolute value of the HOMO energy level of the third compound is 0.01 eV to 0.30 eV.

Abstract: An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: M(L1)n1(L2)n2??Formula 1 wherein, in Formula 1, M, L1, L2, n1, and n2 are each described herein.

Abstract: Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the same, and an electronic apparatus including the organic light-emitting device: wherein, in Formula 1, Y2, ring CY1, ring CY2, T1, T2, A1 to A7, a1, and a2 are as defined in the specification.

Abstract: Disclosed are an organometallic compound represented by Formula 1, an organic light-emitting device including the same, and an electronic device including the organic light-emitting device: The detailed description of Formula 1 is the same as described in the present specification.

Abstract: An organic light-emitting device including a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second electrode, wherein the organic layer includes an emission layer, the emission layer includes a host, a dopant, and a sensitizer, the host does not include a metal atom, the dopant emits light, and the light has a decay time of about 100 nanoseconds or less, and the sensitizer includes an organometallic compound represented by one selected from Formulae 1 and 2 described in the specification.

Abstract: An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: